Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis.
Janus kinase inhibitor
calcineurin inhibitor
eczema
network meta‐analysis
systematic review
topical steroid
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
ISSN: 1365-2222
Titre abrégé: Clin Exp Allergy
Pays: England
ID NLM: 8906443
Informations de publication
Date de publication:
02 Sep 2024
02 Sep 2024
Historique:
received:
29
07
2024
accepted:
07
08
2024
medline:
2
9
2024
pubmed:
2
9
2024
entrez:
2
9
2024
Statut:
aheadofprint
Résumé
Eczema is the most burdensome skin condition worldwide and topical anti-inflammatory treatments are commonly used to control symptoms. The relative effectiveness and safety of different topical anti-inflammatory treatments is uncertain. Network meta-analysis performed within a Cochrane systematic review to compare and statistically rank efficacy and safety of topical anti-inflammatory eczema treatments. Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries to June 2023. Included trials were within-participant or between-participant randomised controlled trials. Participants had eczema that was not clinically infected and was not contact dermatitis, seborrheic eczema or hand eczema. Interventions were topical anti-inflammatory treatments but not complementary treatments, antibiotics alone, wet wraps, phototherapy or systemic treatments. Comparators were no treatment/vehicle or another topical anti-inflammatory. We identified 291 trials (45,846 participants), mainly in high-income countries. Most were industry-funded with median 3 weeks treatment duration. Risk of bias assessed using the Cochrane Risk of Bias 2.0 tool was high in 89% of trials, mainly due to risk of selective reporting. Network meta-analysis of binary outcomes ranked potent and/or very potent topical steroids, tacrolimus 0.1% and ruxolitinib 1.5% among the most effective treatments for improving patient-reported symptoms (40 trials, all low confidence) and clinician-reported signs (32 trials, all moderate confidence). For investigator global assessment, the Janus kinas inhibitors ruxolitinib 1.5%, delgocitinib 0.5% or 0.25%, very potent/potent topical steroids and tacrolimus 0.1% were ranked as most effective (140 trials, all moderate confidence). Continuous outcome data were mixed. Local application site reactions were most common with tacrolimus 0.1% (moderate confidence) and crisaborole 2% (high confidence) and least common with topical steroids (moderate confidence). Skin thinning was not increased with short-term use of any topical steroid potency (low confidence) but skin thinning was reported in 6/2044 (0.3%) participants treated with longer-term (6-60 months) topical steroids. Potent topical steroids, Janus kinase inhibitors and tacrolimus 0.1% were consistently ranked as among the most effective topical anti-inflammatory treatments for eczema.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Institute for Health and Care Research
ID : NIHR201993
Informations de copyright
© 2024 The Author(s). Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
Références
S. de Lusignan, H. Alexander, C. Broderick, et al., “The Epidemiology of Eczema in Children and Adults in England: A Population‐Based Study Using Primary Care Data,” Clinical and Experimental Allergy 51, no. 3 (2021): 471–482.
S. M. Langan, A. R. Mulick, C. E. Rutter, et al., “Trends in Eczema Prevalence in Children and Adolescents: A Global Asthma Network Phase I Study,” Clinical and Experimental Allergy 53, no. 3 (2023): 337–352.
R. J. Hay, N. E. Johns, H. C. Williams, et al., “The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions,” Journal of Investigative Dermatology 134, no. 6 (2014): 1527–1534.
A. Paolino, H. Alexander, C. Broderick, and C. Flohr, “Non‐biologic Systemic Treatments for Atopic Dermatitis: Current State of the Art and Future Directions,” Clinical and Experimental Allergy 53 (2023): 495–510.
E. David, B. Ungar, Y. Renert‐Yuval, P. Facheris, E. Del Duca, and E. Guttman‐Yassky, “The Evolving Landscape of Biologic Therapies for Atopic Dermatitis: Present and Future Perspective,” Clinical and Experimental Allergy 53 (2023): 156–172.
S. R. Wilkes, H. Nankervis, E. Tavernier, A. Maruani, and H. C. Williams, “How Clinically Relevant Are Treatment Comparisons of Topical Calcineurin Inhibitor Trials for Atopic Eczema?” Journal of Investigative Dermatology 136, no. 10 (2016): 1944–1949.
H. C. Williams, “New Topical Treatments for Atopic Dermatitis: Active Comparators Are Needed,” Journal of the American Academy of Dermatology 85, no. 4 (2021): 1065–1066.
D. K. Chu, A. W. L. Chu, D. G. Rayner, et al., “Topical Treatments for Atopic Dermatitis (Eczema): Systematic Review and Network Meta‐Analysis of Randomized Trials,” Journal of Allergy and Clinical Immunology 152, no. 6 (2023): 1493–1519.
L. Steele, B. Stuart, E. Axon, et al., “Topical Anti‐Inflammatory Treatments for Eczema: Network Meta‐Analysis,” Cochrane Database of Systematic Reviews 2022, no. 7 (2022): CD015064.
S. G. Johansson, T. Bieber, R. Dahl, et al., “Revised Nomenclature for Allergy for Global Use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003,” Journal of Allergy and Clinical Immunology 113, no. 5 (2004): 832–836.
S. J. Lax, J. Harvey, E. Axon, et al., “Strategies for Using Topical Corticosteroids in Children and Adults With Eczema,” Cochrane Database of Systematic Reviews 3, no. 3 (2022): CD013356.
J. Schmitt, P. I. Spuls, K. S. Thomas, et al., “The Harmonising Outcome Measures for Eczema (HOME) Statement to Assess Clinical Signs of Atopic Eczema in Trials,” Journal of Allergy and Clinical Immunology 134, no. 4 (2014): 800–807.
P. I. Spuls, L. A. A. Gerbens, E. Simpson, et al., “Patient‐Oriented Eczema Measure (POEM), a Core Instrument to Measure Symptoms in Clinical Trials: A Harmonising Outcome Measures for Eczema (HOME) Statement,” British Journal of Dermatology 176, no. 4 (2017): 979–984.
J. M. Hanifin, M. Thurston, M. Omoto, R. Cherill, S. J. Tofte, and M. Graeber, “The Eczema Area and Severity Index (EASI): Assessment of Reliability in Atopic Dermatitis. EASI Evaluator Group,” Experimental Dermatology 10, no. 1 (2001): 11–18.
B. Kunz, A. P. Oranje, L. Labreze, J. F. Stalder, J. Ring, and A. Taieb, “Clinical Validation and Guidelines for the SCORAD Index: Consensus Report of the European Task Force on Atopic Dermatitis,” Dermatology 195, no. 1 (1997): 10–19.
A. Y. Finlay and G. K. Khan, “Dermatology Life Quality Index (DLQI)—a Simple Practical Measure for Routine Clinical Use,” Clinical and Experimental Dermatology 19, no. 3 (1994): 210–216.
L. M. Howells, J. R. Chalmers, S. Gran, et al., “Development and Initial Testing of a New Instrument to Measure the Experience of Eczema Control in Adults and Children: Recap of Atopic Eczema (RECAP),” British Journal of Dermatology 183, no. 3 (2020): 524–536.
D. M. Pariser, E. L. Simpson, A. Gadkari, et al., “Evaluating Patient‐Perceived Control of Atopic Dermatitis: Design, Validation, and Scoring of the Atopic Dermatitis Control Tool (ADCT),” Current Medical Research and Opinion 36, no. 3 (2020): 367–376.
Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.22021 (Chichester, UK: Wiley, 2021).
I. R. White, “Network Meta‐Analysis,” Stata Journal 15 (2015): 951–985.
A. Chaimani, J. P. Higgins, D. Mavridis, P. Spyridonos, and G. Salanti, “Graphical Tools for Network Meta‐Analysis in STATA,” PLoS One 8, no. 10 (2013): e76654.
A. A. Veroniki, H. S. Vasiliadis, J. P. Higgins, and G. Salanti, “Evaluation of Inconsistency in Networks of Interventions,” International Journal of Epidemiology 42, no. 1 (2013): 332–345.
J. A. C. Sterne, J. Savovic, M. J. Page, et al., “RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials,” BMJ 366 (2019): l4898.
A. Nikolakopoulou, J. P. T. Higgins, T. Papakonstantinou, et al., “CINeMA: An Approach for Assessing Confidence in the Results of a Network Meta‐Analysis,” PLoS Medicine 17, no. 4 (2020): e1003082.
M. J. Page, J. E. McKenzie, P. M. Bossuyt, et al., “The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews,” BMJ 372 (2021): n71.
B. Hutton, G. Salanti, D. M. Caldwell, et al., “The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta‐Analyses of Health Care Interventions: Checklist and Explanations,” Annals of Internal Medicine 162, no. 11 (2015): 777–784.
S. J. Lax, E. Van Vogt, B. Candy, et al., “Topical Anti‐Inflammatory Treatments for Eczema: Network Meta‐Analysis,” Cochrane Database of Systematic Reviews 2024 (2024): CD015064.
S. Reitamo, J. P. Ortonne, C. Sand, et al., “A Multicentre, Randomized, Double‐Blind, Controlled Study of Long‐Term Treatment With 0.1% Tacrolimus Ointment in Adults With Moderate to Severe Atopic Dermatitis,” British Journal of Dermatology 152, no. 6 (2005): 1282–1289.
T. A. Luger, M. Lahfa, R. Folster‐Holst, et al., “Long‐Term Safety and Tolerability of Pimecrolimus Cream 1% and Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis,” Journal of Dermatological Treatment 15, no. 3 (2004): 169–178.
B. Sigurgeirsson, A. Boznanski, G. Todd, et al., “Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5‐Year Randomized Trial,” Pediatrics 135, no. 4 (2015): 597–606.
J. Harvey, S. J. Lax, A. Lowe, et al., “The Long‐Term Safety of Topical Corticosteroids in Atopic Dermatitis: A Systematic Review,” Skin Health & Disease 3, no. 5 (2023): e268.
Y. Ohya and K. Yamamoto‐Hanada, “Management of Infant Atopic Eczema to Prevent Severe Eczema and Food Allergy,” Clinical and Experimental Allergy (2024). (in press): https://doi.org/10.1111/cea.14515.
K. Yamamoto‐Hanada, T. Kobayashi, M. Mikami, et al., “Enhanced Early Skin Treatment for Atopic Dermatitis in Infants Reduces Food Allergy,” Journal of Allergy and Clinical Immunology 152, no. 1 (2023): 126–135.
B. Helfer, J. Leonardi‐Bee, A. Mundell, et al., “Conduct and Reporting of Formula Milk Trials: Systematic Review,” BMJ 375 (2021): n2202.
R. J. Boyle and M. H. Shamji, “What Does Clinical and Experimental Allergy Mean by ‘Trusted Evidence in Allergy’?” Clinical and Experimental Allergy 53, no. 1 (2023): 4–6.
E. Van Vogt, S. Cro, V. R. Cornelius, et al., “Individual Participant Data Meta‐Analysis Versus Aggregate Data Meta‐Analysis: A Case Study in Eczema and Food Allergy Prevention,” Clinical and Experimental Allergy 52, no. 5 (2022): 628–645.
M. M. Kelleher, R. Phillips, S. J. Brown, et al., “Skin Care Interventions in Infants for Preventing Eczema and Food Allergy,” Cochrane Database of Systematic Reviews 11, no. 11 (2022): CD013534.